Weaker expectations for the oil & gas business
07/11/19 -"This led to an impairment (92% for goodwill) on the former Rhodia and Chemlogics activities (Novecare – Advance Formulations), which damaged the Q3 figures and came fully out of the blue. In ..."
Pages
64
Language
English
Published on
07/11/19
You may also be interested by these reports :
23/04/24
Akzo’s Q1 delivered a strong set of consensus-beating figures (sales: +1.9%; adjusted EBITDA: +4.3%; net profit: +23.4%). After all the past trouble ...
22/04/24
Downgrade to Add – New target price EUR 85
19/04/24
Disappointing on first sight, but well in-line with our investment case on second glance
16/04/24
Supporting fundamentals & no more Kottmann items